Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Role of 5-HT1A Receptor Stimulation in the Medial Prefrontal Cortex in the Sustained Antidepressant Effects of Ketamine
Kenichi Fukumoto, Michihiko Iijima, Takeo Funakoshi, et al.
The International Journal of Neuropsychopharmacology (2017) Vol. 21, Iss. 4, pp. 371-381
Open Access | Times Cited: 77

Showing 1-25 of 77 citing articles:

Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders
Simone B. Sartori, Nicolas Singewald
Pharmacology & Therapeutics (2019) Vol. 204, pp. 107402-107402
Open Access | Times Cited: 206
Ketamine: A tale of two enantiomers
Luke A. Jelen, Allan H. Young, James Stone
Journal of Psychopharmacology (2020) Vol. 35, Iss. 2, pp. 109-123
Open Access | Times Cited: 163
The 5-HT1A receptor: Signaling to behavior
Paul R. Albert, Faranak Vahid-Ansari
Biochimie (2018) Vol. 161, pp. 34-45
Closed Access | Times Cited: 158
Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function
Ronald S. Duman, Ryota Shinohara, Manoela V. Fogaça, et al.
Molecular Psychiatry (2019) Vol. 24, Iss. 12, pp. 1816-1832
Open Access | Times Cited: 129
Transient Stimulation with Psychoplastogens Is Sufficient to Initiate Neuronal Growth
Calvin Ly, Alexandra C. Greb, Maxemiliano V. Vargas, et al.
ACS Pharmacology & Translational Science (2020) Vol. 4, Iss. 2, pp. 452-460
Open Access | Times Cited: 87
Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants
Bashkim Kadriu, Maximillian Greenwald, Ioline D. Henter, et al.
The International Journal of Neuropsychopharmacology (2020) Vol. 24, Iss. 1, pp. 8-21
Open Access | Times Cited: 81
Emerging evidence for the antidepressant effect of cannabidiol and the underlying molecular mechanisms
Gabriela Pandini Silote, Ariandra Guerini Sartim, Amanda J. Sales, et al.
Journal of Chemical Neuroanatomy (2019) Vol. 98, pp. 104-116
Closed Access | Times Cited: 76
Ketamine for depression
Luke A. Jelen, James Stone
International Review of Psychiatry (2021) Vol. 33, Iss. 3, pp. 207-228
Closed Access | Times Cited: 70
The molecular pathophysiology of depression and the new therapeutics
Haihua Tian, Zhenyu Hu, Jia Xu, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 65
Perspectives for therapy of treatment‐resistant depression
Mariusz Papp, Wiesław Jerzy Cubała, Łukasz Świȩcicki, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 17, pp. 4181-4200
Open Access | Times Cited: 61
Novel Pharmacological Approaches to the Treatment of Depression
Elias Elias, Ariel Y. Zhang, Melissa T. Manners
Life (2022) Vol. 12, Iss. 2, pp. 196-196
Open Access | Times Cited: 48
The Serotonin 1A (5-HT1A) Receptor as a Pharmacological Target in Depression
Alexander L. W. Smith, Catherine J. Harmer, Philip J. Cowen, et al.
CNS Drugs (2023) Vol. 37, Iss. 7, pp. 571-585
Closed Access | Times Cited: 27
(R)-Ketamine Induces a Greater Increase in Prefrontal 5-HT Release Than (S)-Ketamine and Ketamine Metabolites via an AMPA Receptor-Independent Mechanism
Yukio Ago, Wataru Tanabe, Momoko Higuchi, et al.
The International Journal of Neuropsychopharmacology (2019) Vol. 22, Iss. 10, pp. 665-674
Open Access | Times Cited: 73
Role of Serotonin and Noradrenaline in the Rapid Antidepressant Action of Ketamine
Xavier López-Gil, Laura Jiménez-Sánchez, Leticia Campa, et al.
ACS Chemical Neuroscience (2019) Vol. 10, Iss. 7, pp. 3318-3326
Open Access | Times Cited: 58
Translating biased agonists from molecules to medications: Serotonin 5-HT1A receptor functional selectivity for CNS disorders
Adrian Newman‐Tancredi, Ronan Depoortère, Mark S. Kleven, et al.
Pharmacology & Therapeutics (2021) Vol. 229, pp. 107937-107937
Closed Access | Times Cited: 54
Genetic, epigenetic and posttranscriptional mechanisms for treatment of major depression: the 5-HT1A receptor gene as a paradigm
Paul R. Albert, Brice Le François, Faranak Vahid-Ansari
Journal of Psychiatry and Neuroscience (2019) Vol. 44, Iss. 3, pp. 164-176
Open Access | Times Cited: 52
Rodent ketamine depression-related research: Finding patterns in a literature of variability
Andrew J. Polis, Paul J. Fitzgerald, Pho J. Hale, et al.
Behavioural Brain Research (2019) Vol. 376, pp. 112153-112153
Open Access | Times Cited: 45
Neurobiology of the Rapid-Acting Antidepressant Effects of Ketamine: Impact and Opportunities
Ryota Shinohara, George K. Aghajanian, Chadi G. Abdallah
Biological Psychiatry (2020) Vol. 90, Iss. 2, pp. 85-95
Closed Access | Times Cited: 44
Overcoming Resistance to Selective Serotonin Reuptake Inhibitors: Targeting Serotonin, Serotonin-1A Receptors and Adult Neuroplasticity
Faranak Vahid-Ansari, Min Zhang, Amin Zahrai, et al.
Frontiers in Neuroscience (2019) Vol. 13
Open Access | Times Cited: 43
Medial PFC AMPA receptor and BDNF signaling are required for the rapid and sustained antidepressant-like effects of 5-HT1A receptor stimulation
Kenichi Fukumoto, Manoela V. Fogaça, Rong-Jian Liu, et al.
Neuropsychopharmacology (2020) Vol. 45, Iss. 10, pp. 1725-1734
Open Access | Times Cited: 39
Biased agonism in drug discovery: Is there a future for biased 5-HT1A receptor agonists in the treatment of neuropsychiatric diseases?
Kinga Sałaciak, Karolina Pytka
Pharmacology & Therapeutics (2021) Vol. 227, pp. 107872-107872
Open Access | Times Cited: 34
Inhibition of FKBP51 induces stress resilience and alters hippocampal neurogenesis
Martin G. Codagnone, Nirit Kara, Anna Ratsika, et al.
Molecular Psychiatry (2022) Vol. 27, Iss. 12, pp. 4928-4938
Open Access | Times Cited: 23
mGlu2/3 receptor antagonists for depression: overview of underlying mechanisms and clinical development
Shigeyuki Chaki, Mai Watanabe
European Archives of Psychiatry and Clinical Neuroscience (2023) Vol. 273, Iss. 7, pp. 1451-1462
Closed Access | Times Cited: 15
Astrocytes activation contributes to the antidepressant-like effect of ketamine but not scopolamine
Yun Wang, Liming Xie, Ce Gao, et al.
Pharmacology Biochemistry and Behavior (2018) Vol. 170, pp. 1-8
Closed Access | Times Cited: 39
The 5-HT1A receptor biased agonists, NLX-204 and NLX-101, like ketamine, elicit rapid-acting antidepressant activity in the rat chronic mild stress model via cortical mechanisms
Mariusz Papp, Piotr Gruca, Ewa Litwa, et al.
Journal of Psychopharmacology (2024) Vol. 38, Iss. 7, pp. 661-671
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top